---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-007012"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T14:47:25.505904+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics raises $80M in PIPE led by Enavate; extends cash runway to 2026

## Summary
- Issues 25M shares at $3.21 each for gross proceeds of ~$80M; closing expected by Nov 8, 2022.
- PIPE led by Enavate Sciences with participation from Janus Henderson, Vivo Capital, OrbiMed, and others.
- New director James P. Boylan (CEO of Enavate) appointed to board, effective upon closing.
- Proceeds to fund CTX-009, CTX-471, CTX-8371 clinical programs and preclinical work; cash runway extended into 2026.

## SEC filing metadata
- accession: 0001171843-22-007012
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 5.02, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184322007012/0001171843-22-007012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184322007012/f8k_110222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-007012
- JSON: https://secwatch.observer/filing/0001171843-22-007012.json
- Plain text: https://secwatch.observer/filing/0001171843-22-007012.txt

## Key facts
- Executive change
  James P. Boylan was appointed as Director at Compass Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On November 1, 2022, the Board appointed Mr. Boylan to join as a director of the Board, effective upon the closing of the Private Placement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184322007012/0001171843-22-007012-index.htm
- Material Agreements
  Compass Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $80 million (effective 2022-11-02).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: approximately $80 million
  - Effective: 2022-11-02
  source text: On November 2, 2022, Compass Therapeutics, Inc. (the “Company”) and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of 25,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a purchase price of $3.21 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184322007012/0001171843-22-007012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.